Abstract library

12 results for "Wild".
#845 Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy
Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Alexa Childs
Authors: Childs A, Kirkwood A, Lee A, Caplin M, ...
Keywords: chemotherapy, Ki-67
#1372 The Role of Interval CT Scanning in Patients Undergoing Palliative Chemotherapy for Metastatic Neuroendocrine Tumours (NETs)
Introduction: In NET, radiological response to chemotherapy is often delayed and the importance of interval-imaging during treatment has not been determined.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Rowan Miller
Authors: Miller R, Childs A, Gillmore R, Mayer A, ...
#1415 Detection of SSTR2 and 5 Expression on Circulating Tumour Cells in Neuroendocrine Tumours
Introduction: Neuroendocrine tumours (NET) overexpress somatostatin receptors (SSTR) which can be targeted for therapy with somatostatin analogues (SSA) or radionuclide treatment.
Conference: 13th Annual ENETS conference (2016)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: DR Alexa Childs
Authors: Childs A, Vesely C, Ensell L, Luong T, ...
Keywords: CTC, SSTR
#1442 Somatic Variant Detection in Circulating Cell-Free Plasma DNA of Patients with Pancreatic Neuroendocrine Tumours
Introduction: Cell-free DNA (cfDNA) as a type of “liquid biopsy” represents an attractive alternative to tissue sampling for detecting tumour-specific changes (circulating tumour DNA; ctDNA).
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr Christodoulos Pipinikas
Keywords: ctDNA, PNET
#2022 CXCR4 Expression on Circulating Tumor Cells (CTCs) and Their Association with Bone Metastases in Patients with Neuroendocrine Tumors (NET)
Introduction: Bone metastases have been described in up to 32% of NET patients and are associated with a worse clinical outcome. Overexpression of CXCR4 in primary tumors appears predictive of skeletal involvement.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Francesca Maria Rizzo
Keywords: CTC, CXCR4, bone
#2162 Single Cell Copy Number Variation Analysis (CNV) of Circulating Tumor Cells (CTCs) in Neuroendocrine Tumor (NET) Patients
Introduction: The identification and characterization of CTCs as part of a minimally invasive “liquid biopsy” provides an opportunity to explore NET biology, identify therapeutic targets and investigate tumour heterogeneity.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr Alexa Childs
Authors: Childs A, Vesely C, Rizzo F M, Ensell L, ...
#2199 Systematic Evaluation of the Immune Microenvironment of Neuroendocrine Tumors (NET)
Introduction: Immunotherapy is being explored in many tumour types with encouraging results, but
its role in the management of NET is yet to be defined.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Clare Vesely
#47 Plasma CCN2/connective tissue growth factor is associated with right ventricular dysfunction in Patients with Neuroendocrine Tumors
Introduction: Carcinoid heart disease (CHD) is a known complication of neuroendocrine tumors (NETs), particularly of those arising from the small intestine, appendix and proximal colon (previously known as mid-gut carcinoids). CHD is characterized by right heart fibrotic lesions and has traditionally been defined by the degree of valvular involvement, most commonly in the form of tricuspid regurgitation. Right ventricular (RV) dysfunction due to mural involvement may also be a manifestation. Connective tissue growth factor (CCN2) is upregulated in many fibrotic disorders. Increased tumor expression of CCN2 has been shown in patients with small intestinal NETs associated with peritoneal fibrosis. At present, its role in carcinoid heart disease is unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Deidi S Bergestuen
#122 Molecular genetic findings in gastric carcinoid suggest possible neurofibromin/Ras pathway involvement in carcinoid pathogenesis
Introduction: The molecular pathogenesis of gastrointestinal carcinoid tumours is poorly understood. We have been undertaking molecular genetic investigations of a young woman with neurofibromatosis type 1 (NF1) in whom a gastric carcinoid tumor was detected following an episode of gastrointestinal bleeding. She was otherwise relatively mildly affected by NF1. In NF1, gastric carcinoids have been found previously only in patients with other predisposing factors, which were absent in this patient.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Edward S Tobias
#815 The Effect of Autophagy Inhibitors Alone or in Combination with mTOR Inhibitors in a Neuroendocrine Tumor Cell Model
Introduction: Most patients with neuroendocrine tumors (NETs) require systemic treatment, often with a limited therapeutic effect. RAD001 and Torin1 are mTOR inhibitors (mTORi) known to suppress cell proliferation in NETs. However, cancer cells may use mTORi-induced autophagy to escape the anti-proliferative effect and to prolong cell survival. Chloroquine (CQ) and hydroxychloroquine (HCQ) inhibit autophagy.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr. Simona Glasberg